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SHIVKU2 replicates to high levels in inoculated macaques and reproducibly causes an acute depletion of CD4
1 T cells. We
evaluated the ability of treatment with the antiretroviral drug 9-R-(2-phosphonomethoxypropyl)adenine (PMPA; tenofovir),
begun 7 days postinoculation, to inhibit viral replication and associated pathogenesis. Highly productive infection (plasma
viral RNA . 106 copy eq/mL) was present and CD4 depletion had started when treatment was initiated. PMPA treatment was
associated with a rapid decline in plasma viral RNA to undetectable levels, with parallel decreases in the infectivity of plasma
and infectious cells in PBMCs and CSF and stabilization of CD41T-cell levels. Viral dynamics parameters were calculated for
the initial phase of exponential viral replication and the treatment-related decline in plasma viremia. Following cessation of
treatment after 12 weeks, plasma viral RNA was detectable intermittently at low levels, and spliced viral transcripts were
detected in lymph nodes. Although treatment was begun after viral dissemination, high viremia, and CD4 decreases had
occurred, following withdrawal of PMPA, CD41 T-cell counts normalized and stabilized in the normal range, despite persistent
low-level infection. No PMPA-resistance mutations were detected. These results validate the similar viral replicative
dynamics of SHIVKU2 and HIV and SIV, and also underscore the potential for long-term modulation of viral replication patterns
and clinical course by perturbation of primary infection. © 2000 Academic Press
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SHIVKU2 is a virulent quasispecies obtained following
ultiple animal passages from a chimeric SHIV contain-
ng the tat, rev, vpu, and env genes of HIV-1 HXB2c on the
background of SIVmac239. After intravenous or mucosal
inoculation in rhesus macaques, the virus is acutely
pathogenic, replicating to high levels and reproducibly
producing a characteristic and almost complete deple-
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306tion of CD41 T cells within weeks of infection, with
subsequent development of simian AIDS (Joag et al.,
1997).
The acyclic nucleoside phosphonate tenofovir [9-R-(2-
phosphonomethoxypropyl)adenine (PMPA)] is a potent
inhibitor of retroviruses and hepadnaviruses, including
the human immunodeficiency viruses (types 1 and 2),
simian immunodeficiency viruses (SIV), and hepatitis B
virus (reviewed in DeClercq, 1997). This class of drugs is
converted intracellularly to the diphosphorylated deriva-
tive (the nucleoside triphosphate analog) that acts as a
chain terminator of the reverse transcriptase reaction
(Balzarini et al., 1991). The drug has been shown to
produce dramatic reduction of viral replication in chron-
ically SIV-infected macaques (Van Rompay et al., 1996;
Tsai et al., 1997; Nowak et al., 1997), although when
treatment was stopped, viral load rebounded to pretreat-
ment levels. Short-term postinoculation (p.i.) treatment
has been shown to prevent establishment of persistent
SIV infection in macaques. However, both the delay be-
tween inoculation and initiation of treatment and the
duration of treatment critically influenced the efficacy of
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307MODULATION OF SHIVKU2 AFTER PMPA TREATMENT OF MACAQUESsuch treatment, which needed to be initiated within 24 h
p.i. for optimal effectiveness (Tsai et al., 1995, 1998).
In the present study, we evaluated the ability of short-
term PMPA treatment, begun 7 days following intrave-
nous inoculation with SHIVKU2, a time when extensive
disseminated infection was already present, to inhibit
viral replication and associated pathogenesis. The re-
sults demonstrated that transient antiretroviral treatment,
initiated after substantial viral replication and pathogenic
effect had already begun, produced long-lasting modu-
lation of viral replication patterns and halted and re-
versed the subtotal depletion of CD41 T cells that typi-
ally characterizes infection with SHIVKU2. These effects,
hich persisted long after cessation of drug treatment,
ere presumably the result of the development of adap-
ive host responses (A. Kumar et al., submitted), facili-
ated by pharmacologic suppression of viral replication.
nderstanding the underlying mechanisms could have
rofound implications for strategies to develop a suc-
essful vaccine against HIV.
RESULTS
rogression of untreated SHIVKU2 infection in rhesus
macaques
Seven control rhesus macaques were inoculated with
104 animal infectious doses of pathogenic SHIVKU2, and
were studied over the course of several months (52A,
52B, 57W, 57Y), or intensively over 1–2 weeks, followed
by full necropsy at Days 6, 11, and 18 (54T, 54S, and 54U,
respectively). The CD4:CD8 ratios in these animals
dropped rapidly, over the first several weeks, to under
0.25 (Fig. 1A), while the numbers of infectious cells per
million PBMC (ICA) initially increased to 1000–10,000,
then leveled off at around 10 (Figs.1B and 1C) upon
resolution of the primary infection. The plasma virus load
was determined daily in the three intensively studied
macaques and showed a rapid rise to a peak of 3.8 3 108
to 1.7 3 109 in 54S and 54U at Day 10 p.i., followed by the
beginning of resolution of the primary viremia (Fig. 1D),
with a drop in CD4:CD8 ratio starting at Day 8. The
plasma samples from 54T from the first few days of
infection were not suitable for amplification because of
technical problems. Infectious virus was present in
lymph node, spleen, lung, and plasma by Day 6 at nec-
ropsy of macaque 54T, and detectable viral RNA and
DNA were detected in regions of the brain at Day 6 p.i.
(S. Buch et al., manuscript in preparation). Longer-term
plasma virus loads in infected control animals 57W and
57Y are shown in Fig. 1E.
Study objectives
Based on the analysis of the control animals de-
scribed above, we chose to start treatment of SHIVKU2-
infected macaques at 1 week postinfection, to allow thevirus sufficient time to establish a disseminated infection
throughout the body. Two rhesus macaques were inoc-
ulated intravenously with 104 animal infectious doses of
pathogenic SHIVKU2; after 1 week, they were started on
daily injections of PMPA (30 mg/kg/day subcutaneously).
Antiviral treatment was administered for approximately
12 weeks (83 days), and then discontinued. Longitudinal
blood and CSF samples were obtained frequently during
treatment and after the discontinuation of treatment for
assays of infectious viremia, infectious cells in the PBMC
and CSF, and plasma virus load (real-time RT-PCR). As
the study objective was to evaluate the impact of treat-
ment on SHIVKU2 infection, rather than prevent the estab-
ishment of persistent infection, initiation of PMPA treat-
ent was intentionally delayed until 1 week p.i., based
n characterization of the kinetics of viral replication and
D41 T-cell loss in untreated macaques infected with
SHIVKU2, to allow dissemination of the infection and the
beginning of the process of CD41 T-cell loss.
retreatment viral dynamics
The time course of the study can be conveniently
ivided into three periods: postinoculation but pretreat-
ent, on treatment, and off treatment (“rebound”). Follow-
ng inoculation, viral replication rapidly increased, as
emonstrated by all viral load parameters. By Day 7 p.i.,
ust prior to initiating PMPA treatment, plasma viral load
ad reached nearly 107 copy eq/mL in both animals (45P
and 45Q), and cell-associated infectious virus rose to
1000/106 PBMC, with culturable cell-associated virus de-
monstrable in the CSF and a loss of circulating CD41 T
ells to less than one-third of preinoculation values (45P,
2%; 45Q, 32%; Figs. 1A, 1B, and 1E). In comparison, the
D4:CD8 ratios of four rhesus macaques (52A, 52B, 57W,
7Y) inoculated with SHIVKU2 with the same stock, but
which were left untreated by antiviral therapy, underwent
a rapid decline by 4 weeks (Fig. 1A). Estimation of the
plasma virus exponential growth rates (r0) and doubling
times (t2) during the period of maximal exponential in-
rease and the basic reproductive ratios (R0) for the
reated SHIVKU2-infected macaques gave values compa-
rable to those determined for SIV (Nowak et al., 1997)
(Table 1). The short-term time course of plasma virus
load is shown for the treated animals and, additionally,
for three untreated animals, 54S, 54T, 54U, in Fig. 1D. The
results indicated that the peak in primary infection virus
load in untreated macaques occurred at approximately
Days 10–11, after which the characteristic decrease in
plasma viral load associated with resolution of the pri-
mary infection began.
Virus control during PMPA treatment
PMPA treatment of two animals was initiated at Day
7 p.i., with a single daily dose of 30 mg/kg, subcutane-
ously. This dosage regimen has been shown previously
(les ass
308 SMITH ET AL.to be effective in inhibiting SIV replication in macaques
(Van Rompay et al., 1998; Nowak et al., 1997). Plasma
samples were obtained starting at Day 7, just before the
first PMPA injection. Following initiation of PMPA treat-
ment, plasma viral RNA continued to increase for an
additional 3 days, reaching maximum values of 3–8 3
107 copy eq/mL (compared to 0.4–1.7 3 109 in untreated
FIG. 1. Time course of virus infection measures and CD4:CD8 ratio
treatment period, and posttreatment follow-up period. PMPA was conti
SHIVKU2-infected animals without treatment, 52A, 52B (E, ), 57W, 57Y (
[45P (); 45Q (f); 57W (3); 57Y (l)]. No infectious cells detected per 10
2) cultures for infectious cells from cerebrospinal fluid from 45P and 45
macaques 54S (L), 54T (M), and 54U (*). (D) Early weeks of plasma vi
and 54U. Macaque 54S (L); 54T (M); 54U (*); 45P (); 45Q (f). (E) Pla
of PMPA treatment. Control infected macaques 57W (3); 57Y (l). Samp
of plasma analyzed) are plotted as those values (log 5 2.48 or 2.78).54T and 54U), and then began to decline sharply, de-
creasing to approach the threshold of detection (300 to600 copy eq/mL, for 1.0 or 0.5 ml plasma analyzed)
approximately 4 weeks later (Figs. 1D and 1E). The de-
cline in plasma viremia in the treated macaques was
paralleled by decreases in cell-associated viral load in
PBMC and CSF, over approximately the same interval
(Fig. 1B), and in macrophage cultures. Once plasma viral
load decreased to below the threshold of detection, it
treated and treated rhesus macaques during initial infection, PMPA
r 83 days. (A) Time course of CD4:CD8 ratios during infection. Control
treated macaques 45P (); 45Q (f). (B) Infectious cells per 106 PBMC
icated as 0.1 on the ordinate. Below the x axis, positive (1) or negative
Infectious cells per 106 PBMC in early weeks postinfection in untreated
n treated macaques 45P and 45Q, and untreated macaques 54S, 54T,
remia in macaques 45P () and 45Q (f), starting at Day 7 p.i., Day 0
ayed at below 300 or 600 eq/mm3 (the limit of detection for the volumes in un
nued fo
3, l);
6 is ind
Q. (C)
remia i
sma viremained undetectable for the duration of treatment,
while PBMC-associated infectious virus was only inter-
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309MODULATION OF SHIVKU2 AFTER PMPA TREATMENT OF MACAQUESmittently detectable, at very low levels (1 infected cell/106
PBMC; Fig. 1B). Macrophage cultures from both animals
were positive for most time points between Weeks 1 and
6 (0 to 5 weeks of PMPA) and then were uniformly
negative throughout the rest of the treatment period.
Estimation of the upper limit of the infected cell clear-
ance half-life, based on the slope during the interval of
maximum rate of decrease during initial PMPA treatment,
yielded values of 1.16 and 0.99 days (Table 1), consistent
with previous estimates for SIVsmE660 and smE543-3
(Nowak et al., 1997), and HIV-1 (Wei et al., 1995; Ho et al.,
1995; Perelson et al., 1996). The declines in CD41 T-cell
ounts noted prior to starting treatment were also halted,
ith increases from pretreatment levels noted in both
nimals (Fig. 1A). In contrast, the CD4:CD8 ratios in four
ntreated animals showed a rapid decline to ,0.25 in
he first 3 weeks of infection and remained low (Fig. 1A).
By 70 days on treatment, viral load was below the
hreshold of detection in blood and CSF, as measured by
ssays for plasma viral RNA, and cell-associated infec-
ious virus in PBMC and CSF samples. Mesenteric lymph
ode and spleen biopsies obtained at 70 days on treat-
ent were analyzed for the presence of infectious cells;
ne of two lymph nodes from animal 45P was positive at
infected cell per 106 lymph node mononuclear cells,
while two lymph nodes from animal 45Q exhibited ,1
infected cell per 106 PBMC. Spleen biopsies from 45P
T
Viral Dynam
Calculated R0
Animal
Exponential growth phase Delay
r 0 t 2 None Exponential
Treated SHIVKU
45P 1.4 0.49 3.3 8.0
45Q 1.5 0.46 3.2 7.9
Untreated SHIV
54S 2.4 0.29
54T 2.7 0.26
54U 1.5 0.48 2.5 6.1
SIVsmE660- and SIVsmE
Average 2.2 0.32 3.6 11.4
ange (1.66–2.69) (0.26–0.42) (2.2–4.6) (4.2–17)
Note. Parameters modeled include the initial exponential growth rate
no delay, exponentially distributed delay, and fixed delay models; deca
productively infected cells) a; maximum (upper limit) decay half-life for
xponential growth rate r, as described in Nowak et al. (1997). The R 0 v
from the resolution of primary infection, not on treatment.
a Average values and ranges shown for SIV are from Nowak et al. (nd 45Q were positive for infectious cells at frequencies
f 3 and 1 infected cells per 106 cells, respectively.ong-term modulation of virus replication
osttreatment
After 83 days (;12 weeks) on treatment, PMPA was
iscontinued and viral load was monitored. The treat-
ent did not result in clearance of the infection, as
eemergent virus was readily detected in the plasma of
oth animals following discontinuation of PMPA. How-
ver, in striking contrast to the prompt rebound of plasma
irus load to pretreatment levels, as seen following ces-
ation of PMPA treatment of chronically SIV-infected ma-
aques (Van Rompay et al., 1996; Nowak et al., 1997; Tsai
t al., 1997), the rebound of SHIVKU2 following withdrawal
f PMPA was limited, reaching levels of only 1.0–1.5 3
04 copy eq/mL, and did not increase further. Plasma
viremia then declined to below the limit of detection, with
subsequent cycles of transient rises and declines to
below detection limits (Fig. 1E). Peak plasma viremia
levels during these cycles reached levels only 3–4 logs
lower than those seen during the peak of primary infec-
tion and remained consistently lower than those of the
untreated infected macaques, although statistical signif-
icance cannot be shown with this sample size. Compar-
ison of exponential viral growth rates during the initial
phase of primary infection prior to treatment (r0) and in
the period of maximal increase following withdrawal of
treatment (r) demonstrated a decrease in the viral repli-
rametersa
PMPA treatment Off treatment
ixed a t 1/2 r t 2
ed M. mulatta
13.5 0.6 1.16 0.4 1.73
14.0 0.7 0.99 0.8 0.87
ted M. mulatta
10.6
infected M. nemestrinaa
36.5 0.74 1.0 1.23 0.8
.4–68) (0.51–0.96) (0.72–1.36) (0.45–1.77) (0.39–1.54)
sma viral load doubling time t 2; basic reproductive ratio R 0, based on
of plasma virus during treatment (minimum estimate of death rate of
irus and productively infected cells, in days, t 1/2; and the per-day viral
r the untreated animal 54U is based on the downslope a value derivedABLE 1
ics Pa
F
2-infect
KU2-infec
543-3-
(5
r 0; pla
y slope
free v
alue focation rate in the period immediately following discon-
tinuation of antiviral treatment (Table 1); this may be
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310 SMITH ET AL.related to the long intracellular half-life of the phosphor-
ylated tenofovir.
Cultures performed for detection of infectious cells in
CSF through Week 21 (8 weeks off treatment) remained
negative following discontinuation of PMPA (Fig 1B),
while PBMC cultures were intermittently positive, at low
levels (Fig. 1B). Macrophage cultures were positive on 2
of 14 time points for 45P and none of 14 for 45Q in the
posttreatment period. Lymph node mononuclear cells
from 45P and 45Q from 17 weeks posttreatment had 10
and 3 infectious cells per 106, respectively. The status of
iral replication in lymphoid tissues after discontinuation
f PMPA was also examined by RT-PCR. Lymph node
iopsy specimens obtained 2 and 17 weeks after cessa-
ion of treatment were negative for SIV pol RNA by
T-PCR assay, but did show signals upon nested primer
mplification (Fig. 2C, and data not shown). Because
hese viral RNA species could represent either full-length
ranscripts or packaged genomic vRNA in trapped virus
articles, we therefore also performed RT-PCR specific
or multiply spliced viral mRNAs (spanning the tat and rev
xons), as these transcripts are produced only in pro-
uctively infected cells. Direct RT-PCR amplifications
ere negative, but the nested amplifications confirmed
he presence of low-level viral replication (Figs. 2A and
B, Table 2).
Following discontinuation of PMPA treatment, the aver-
ge CD41 T-cell count over Weeks 23–50 was 1675 for 45P
nd 844 for 45Q. The CD4:CD8 normalized and remained in
he normal range throughout 1 year postinoculation, for 9
onths following cessation of drug treatment, in contrast to
he ratios of the long-term infected animals (Fig. 1A).
We sought to determine whether the virus recovered
uring or after withdrawal from treatment showed evi-
ence of the identified PMPA-resistance mutation at
odon 65 (K65R) of the reverse transcriptase (Van
ompay et al., 1996). Virus was passaged once in
CEMX174 cells from positive cultures from Week 14 (two
cultures, 45P) and Week 21 (one culture, 45Q) postinfec-
tion, and one positive CSF culture (Week 6 p.i., 45P).
These viruses were pelleted by ultracentrifugation, the
RNA was extracted, and the region of the pol gene
surrounding the RT codon 65 was amplified by RT-PCR
using primers SIVpolA and -B. The nucleotide sequence
was obtained by DNA sequencing using the internal
SIVpolC primer. The amino acid sequence of codons
65–131 was derived from the nucleotide sequence; only
one silent mutation (that was also present in SHIVKU2)
as noted in all four samples that differed from the
riginal SIVmac239 parent pol gene (CTA to TTA at codon
100). Codon 65 remained the wild-type arginine in all four
isolates. The amino acid sequence in these isolates was
also wild-type at codons 69, 82, and 118, where addi-
tional (possibly compensatory) mutations may arise in
PMPA-resistant virus (Van Rompay et al., 1996, 1999).
tDISCUSSION
SHIVKU2 is a highly pathogenic chimeric virus that re-
producibly undergoes a very high level of viral replication
in inoculated macaques and causes acute, virtually com-
plete loss of CD41 T cells, with subsequent development
of AIDS in these animals. PMPA treatment of SHIVKU2-
noculated macaques, initiated 1 week p.i., at a time
hen disseminated infection and extensive viral replica-
1
FIG. 2. Detection of full-length and multiply spliced viral mRNAs by
RT-PCR of biopsied lymph nodes. RNA was prepared from inguinal
lymph nodes snap-frozen at the time of biopsy (Weeks 2 and 17 after
ending PMPA treatment). Total RNA (1 mg) was amplified by RT-PCR
eaction using SIVpol AB or Mspl AB primers. A 1-ml aliquot of these
eactions was added to nested PCR reactions containing the SIVpol CD
r Mspl BC primers, and a further 40 cycles were run. A 9-ml sample of
the product of the nested reactions was separated by agarose gel
electrophoresis. (A) RT-PCR of multiply spliced viral mRNAs, nested
reactions. RNA was isolated from lymph nodes biopsied 2 weeks after
the PMPA treatment was ended. Lane 1, no RNA in RT-PCR reaction;
lane 2, 45P LN1; lane 3, 45Q LN1; lane 4, 45Q LN2; lane 5, positive
control SHIVKU2-infected cell RNA. Markers: 100-bp markers. (B) RT-PCR
of multiply spliced viral mRNAs, nested reactions with RNA from lymph
node biopsies taken 17 weeks after ending PMPA treatment. Samples
from inner reactions were separated on 4% Nusieve gels. Lane 1, no
RNA in RT-PCR reaction; lanes 2 and 3, 45P LN1; lanes 4 and 5, 45P
LN2; lane 6, positive control SHIVKU2-infected cells. Control reactions 2
and 4 were heated to 95°C 5 min before the RT step. Markers, fX174
HinfI digest (left) and 100-bp markers (right). (C) RNA was obtained from
lymph nodes biopsied 2 weeks after the PMPA treatment was ended.
RT-PCR of full-length viral mRNAs with SIVpol primers, nested reac-
tions. Lane 1, no RNA in RT-PCR reaction; lane 2, 45P LN1; lane 3, 45Q
LN1; lane 4, 45Q LN2; lane 5, positive control SHIVKU2-infected cell RNA.
arkers, 100-bp markers.ion had already been established and CD4 T-cell loss
had begun, led to prompt, virtually complete inhibition of
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311MODULATION OF SHIVKU2 AFTER PMPA TREATMENT OF MACAQUESviral replication and long-term stabilization of CD41 T-
cell levels and CD4:CD8 ratios. Despite decreases in
viral replication on treatment to below the threshold of
detection in multiple different viral load assays, 12 weeks
of treatment did not result in elimination of the virus;
reemergent virus was readily detected in both animals
following discontinuation of treatment. Analysis of viral
dynamics parameters for SHIV calculated from daily
plasma vRNA loads in three untreated and two treated
animals (pretreatment) revealed them to be comparable
to those derived for SIV- and HIV-1-infected subjects
(Nowak et al., 1997; Phillips et al., 1997), supporting the
basic similiarity of virological aspects of the SHIVKU2-
infected macaque as a model system, despite such dif-
ferences as the coreceptor usage and rapidity of CD41
T-cell loss in the peripheral blood.
Perhaps the most striking finding in this study was the
observation that following discontinuation of PMPA treat-
ment, viral replication did not rapidly return to pretreat-
ment levels, despite clear evidence of persistent infec-
tion. In contrast, in previous studies in SIV-infected rhe-
sus, pigtailed, and cynomolgus macaques, in which
PMPA treatment was initiated after establishment of
chronic infection, viral replication returned to pretreat-
ment levels, following discontinuation after various du-
rations of treatment (Nowak et al., 1997; Van Rompay et
al., 1996; Tsai et al., 1997). Short-term PMPA intervention
during the first days following SIV inoculation was capa-
ble of preventing establishment of persistent infection in
some animals, with a suggestion of modulation of viral
replication after discontinuation of drug treatment in
comparison to untreated controls, in those animals in
which persistent infection was not prevented (Tsai et al.,
1995, 1998). In a separate study utilizing HIV-2287 infection
of pigtailed macaques (another nonhuman primate
model of AIDS that, like infection with pathogenic SHIVs,
is characterized by extensive early loss of CD41 T cells),
T
Qualitative Detection of Viral Transcripts in L
Animal, sample Days post-PMPA GAPDH
45P LN1 15 1
45QLN1 15 1a
45QLN2 15 1
45P LN1 123 1
45P LN2 123 1
45QLN1 123 1
45QLN2 123 1
Note. Inguinal lymph node biopsies were obtained at 15 and 123 da
using total RNA purified from lymph nodes and primers for the viral p
Nested or seminested primers were used in further PCR cycles for th
a Weak signal.hort-term intervention in primary infection with the an-
iretroviral drug d4T was associated with long-term mod-
g
nlation of viral replication, sparing of CD41 T-cells, and
rolonged survival, relative to untreated controls (Watson
t al., 1997). Similarly, the use of postinoculation tenofovir
reatment regimens that did not prevent establishment of
ersistent infection with SIVsmE660 resulted in down-
odulation of plasma viremia after cessation of treat-
ent (Lifson et al., 2000). Comparisons between treat-
ent regimens are very important for understanding how
arly treatments may affect the long-term outcomes of
nfection. Indeed, clinical studies of the discontinuation
f HAART in HIV-infected patients are now being widely
eported, with varying times to initiation of treatment with
arious combination antiretroviral regimens and varying
urations before cessation of treatment. One of the major
trengths and important values of animal model systems
s the ability to vary parameters like the time to initiation
f treatment or duration of treatment in a controlled
ashion to facilitate meaningful comparative analysis.
he present study represents an initial step toward this
oal, with the use of a pathogenic SHIV model.
In the present study, treatment was not initiated until 7
ays p.i., a time when infection is widely disseminated in
HIVKU2-infected animals (Joag et al., 1997; S. Buch et al.,
unpublished) and when high levels of circulating virus
were already demonstrable (Fig. 1). Under these condi-
tions, it might have been expected that circulating
plasma virus would return to high levels when drug
treatment was stopped. However, whereas virus did re-
emerge when treatment was halted, peak viral levels
reached the range of only 103–104 copy eq/mL, and then
declined to below the threshold of detection. With con-
tinued follow-up, plasma virus levels showed repeated
cycles of reemergence to blunted peaks and subsequent
decline to below the detection threshold. Although infec-
tion with SHIVKU2 is usually associated with dramatic
epletion of CD41 T cells, in these animals, following
withdrawal of PMPA treatment, circulating CD41 T cells
ode Biopsies after Discontinuation of PMPA
IVpolAB SIVpolCD Msp1AB Msp1BC
2 1 2 2
2 1 2 1
2 1 2 1
2 1 2 1
2 1 2 1
2 1 2 2
2 1 2 1
nd 17 weeks) after stopping PMPA treatment. RT-PCR was performed
ase, for multiply spliced viral mRNA, and the cellular mRNA GAPDH.
tion of viral genes.ABLE 2
ymph N
S
ys (2 a
olymerradually increased to the normal range and remained at
ormal levels over 1 year of follow-up.
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312 SMITH ET AL.As low-level PMPA resistance (EC95 increased about
ivefold) demonstrated after long-term administration of
MPA was shown to be the result of a SIV pol K65R
utation (Van Rompay et al., 1996), we examined the
everse transcriptase coding region for the presence of
his mutation. Despite the delay of antiviral therapy until
he plasma virus loads had attained levels of nearly 107
eq/ml in both animals, virus isolated from the animals
during (the last positive CSF culture) or after (PBMC
cocultures from 14 or 21 weeks p.i.) treatment did not
show any evidence of this or any other potential drug
resistance mutations. In conjunction with a very long
intracellular half-life of the antiviral compound, the de-
crease in virus replication during the early stage of an-
tiviral treatment, as evidenced by the rapid decline in
plasma virus and very low level of lymph node-associ-
ated multiply spliced viral mRNAs, may have been suffi-
ciently rapid to prevent the selection and outgrowth of
PMPA-resistant virus, in a manner similar to that seen in
human HIV-11 patients on triple antiviral therapy (Wong
et al., 1997).
These findings support the hypothesis that short-term
effective therapy early after infection may alter the future
posttreatment course of the infection, even when it does
not eliminate the establishment of that infection. We
previously reported that 30 days of treatment with 9-(2-
phosphonylmethoxyethyl)adenine (PMEA), a related
compound, of SIVmac239-infected rhesus macaques in-
duced prolonged suppression of virus after antiviral
treatment was withdrawn (Joag et al., 1997). A recent
eport provided evidence for similar effects of short-term
MPA treatment in the newborn rhesus macaque–SIV-
mac251 system. Van Rompay et al. (1999) found that new-
born macaques infected at birth and treated on Days
5–65 with PMPA showed a reduction in plasma virus
load by 100- to 1000-fold and showed no signs of AIDS
when euthanized at that time.
Previous reports have demonstrated that provirus and
replication-competent HIV-1 could still be rescued from
PBMC and lymphoid tissues from HIV-1-infected patients
with undetectable levels of plasma viral RNA during
treatment (Wong et al., 1997; Finzi et al., 1997; Chun et al.,
1997). More recently, the presence of replication-compe-
tent virus was demonstrated in seminal cells of men
receiving highly active therapy (Zhang et al., 1998). The
implication that very low levels of virus replication could
occur in some cells, in the absence of detectable plasma
viral RNA, was borne out in new studies of the evolution
over time of the envelope sequence in some patients on
2 to 3 years of highly active antiretroviral therapy (Zhang
et al., 1999) and the demonstration of circular HIV-1 DNA,
evidence of early cellular infection (Furtado et al., 1999),
during such treatment.
This apparent control of viral replication and its con-
sequences is consistent with the development of host
responses during or just after the period of pharmaco-logical control of viral replication that are capable of
holding the infection in check once treatment is with-
drawn. Indeed, our studies are consistent with the pres-
ence of both neutralizing antibodies and CTL activity in
the off-treatment follow-up period (A. Kumar et al., manu-
script submitted). Interestingly, a recently proposed
mathematical model of immune control of viral replica-
tion following transient antiviral treatment predicts recur-
ring damped cycles of viral reemergence and quies-
cence in the chronic phase of infection, exactly as was
observed in the present study (Wodarz and Nowak,
1999).
These observations have important implications both
for understanding the pathogenesis of primate lentivirus
infection and for developing effective vaccines to prevent
infection with these viruses. The observations also focus
attention on the early stages of primary infection as a
particularly dynamic period when even transient modu-
lation of viral replication can produce long-term conse-
quences. Further characterization of the immune re-
sponses associated with control of viral replication fol-
lowing withdrawal of treatment will be of great interest,
along with determination of the long-term viral replication
pattern and clinical course in animals protected. The
insights obtained may be of profound significance for
efforts to develop a vaccine against HIV infection and
AIDS.
MATERIALS AND METHODS
Challenge virus
Stock SHIVKU2 was grown in rhesus macaque PBMC
ultures. It had an infectious titer of approximately 104
TCID50/ml by assay on C8166 cell cultures and by titration
n macaques. Pathogenesis of the virus was reported by
oag et al. (1997)
nimals
The rhesus macaques (Macaca mulatta, 2- to 3-year-
ld males, 4.1–5.5 kg) described in this study were ob-
ained from LABS of Virginia (Yemassee, SC) and were
ndividually housed in accredited facilities of the Univer-
ity of Kansas Medical Center (Association for Assess-
ent and Accreditation of Laboratory Animal Care–Inter-
ational). The animals had been screened serologically
nd were negative for SIV, STLV, and simian retrovirus
efore inoculation. The two PMPA-treated animals (45P,
5Q) were inoculated intravenously with 1 ml undiluted
athogenic SHIVKU2 (Joag et al., 1997) on Day 0; this
represents 104 animal infectious doses determined by
titration of the virus in animals (Foresman et al., 1998).
Seven additional animals (54S, 54T, 54U, 52A, 52B, 57W,
and 57Y) were similarly inoculated with SHIVKU2. The 54S,
54T, and 54U animals were intensively studied, including
the frequent determination of plasma virus load, over the
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313MODULATION OF SHIVKU2 AFTER PMPA TREATMENT OF MACAQUESfirst days to weeks of infection before necropsy (S. Buch
et al., manuscript in preparation). Macaques 52A, 52B,
57W, and 57Y were similarly infected and followed for
approximately 26 weeks, when they were necropsied.
Treatment with PMPA
PMPA was provided by Gilead Sciences (Foster City,
CA). PMPA aqueous solution (pH 7.0) was prepared in
endotoxin-free water and sterile filtered (0.2 mm) as pre-
viously described (Van Rompay et al., 1998), resulting in
a final concentration of 30 mg/ml. Starting at 7 days
postinfection, the animals were injected once daily sub-
cutaneously during the treatment period with 30 mg/kg/
day PMPA. The animals were weighed weekly for adjust-
ment of the treatment.
Processing of samples
Blood for periodic virologic assays and CBCs was
obtained in heparin anticoagulant under ketamine anes-
thesia. Heparinized blood from the femoral vein was
processed as previously described to test for SHIV in-
fectivity in the plasma, for infectious peripheral blood
mononuclear cells, and for CD4 counts (Joag et al., 1997).
Plasma samples for quantitative plasma load measure-
ments were obtained in ACD or EDTA anticoagulant.
Briefly, for quantitative plasma culture, serial dilutions of
plasma were added to C8166 indicator cells for 7 days
and aliquots were transferred to a second plate of cells
for a further 7 days. CSF was obtained periodically under
ketamine anesthesia during the treatment period. Infec-
tious cell assays (ICAs) were also performed from the
cells from cerebrospinal fluid. Mesenteric lymph node
and spleen biopsies were obtained after 10-week PMPA
treatment, single-cell suspensions were prepared, and
infectious cell frequency was assessed as for PBMCs.
Inguinal lymph nodes were obtained 15 days and 17
weeks after discontinuation of PMPA treatment under
ketamine anesthesia. These biopsies were snap-frozen
in liquid nitrogen for RNA purification, and for the 17-
week posttreatment time point, another portion was pro-
cessed for single cells for infectivity assays.
Cell cultures
The human T-cell line C8166 was used as the indicator
line to measure virus infectivity. Cells were cultured at a
concentration of 106/ml in RPMI medium (RPMI 1640
supplemented with 20 mM HEPES buffer, pH 7.3, and 2
mM glutamine) with 10% fetal bovine serum (FBS). PB-
MCs were also cultured in macrophage differentiation
medium containing granulocyte-macrophage colony-
stimulating factor and macrophage colony-stimulating
factor as described previously (Joag et al., 1994a) for the
detection of virus-infected cells.
(
pFluorescence-activated cell-sorting analysis
PBMCs or lymph node cells were reacted with mono-
clonal antibody to CD41 T or CD81 T cells (Dako, Carpin-
teria, CA). After washing, the cells were stained with
fluorescein isothiocyanate (FITC)-conjugated goat anti-
mouse IgG (Dako), fixed in 1% buffered Formalin, and
analyzed on a fluorescence-activated cell counter (Joag
et al., 1994b, 1996).
RT assays
Virus production in cultures was monitored by virus-
associated reverse transcriptase activity, assayed in
50-ml reactions containing 30 ml of clarified supernatant
culture medium and 5 mCi of [3H]dTTP (60–80 Ci/mmol;
ICN Pharmaceuticals, Irvine, CA) and rAdT template-
primer (Pharmacia Laboratories, Piscataway, NJ), as de-
scribed (Smith et al., 1989).
Detection of viral RNA in tissues
Weighed portions of snap-frozen lymph nodes were
homogenized in Trizol Reagent (Life Technologies, Gaith-
ersburg, MD). PBMCs were first isolated by Ficoll–Paque
(Amersham Pharmacia Biotech, Piscataway, NJ), and
lysed in Trizol. Total RNA from both methods was iso-
lated as described by the manufacturer, and the final
RNA was dissolved in 50 ml dH20 per 100 mg original
tissue. The quality of the RNAs was assessed by reverse
transcriptase (RT)-mediated PCR for the cellular gene
glyceraldehyde phosphate dehydrogenase (GAPDH)
mRNA as described (Smith et al., 1997), using the Titan
One-Tube RT-PCR System (Boehringer-Mannheim, India-
napolis, IN). The lack of contaminating DNA in the RNA
preparations was assessed by parallel reactions in
which the RT activity was first inactivated by 2 min at
99°C followed by 3 min at 95°C. If necessary, DNA was
removed with amplification-grade DNase (Life Technol-
ogies), followed by extraction. Total RNA (1 mg) was used
n the one-step reaction containing the manufacturer’s
uffer and enzyme mix, appropriate primers, and 1.6 U
rime RNase inhibitor (5 Prime3 3 Prime, Boulder, CO).
he reactions were performed with a Perkin–Elmer DNA
hermal Cycler 480 with a thermal profile consisting of
2° for 30 min, 1 cycle; 94°C for 5 min, 1 cycle; 94°C for
0 s, 55°C for 30 s, 68°C for 45 s, 10 cycles; 94°C for
0 s, 55°C for 30 s, 68°C for 45 s, with an additional 5-s
xtension/cycle, 25 cycles; 68°C for 6 min. A 9-ml sample
of the product was loaded onto an agarose/TBE gel
containing ethidium bromide, DNA was separated by
electrophoresis, and the gel was photographed. When
no visible product was detected, 1 ml of the initial reac-
tion mixture was added to a nested PCR reaction con-
taining nested primers, 1.5 mM MgCl2, 1.25 U Taq enzyme
Sigma, St. Louis, MO) and a further 40 cycles were
erformed (thermal profile: hot start at 97°C for 1 min
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314 SMITH ET AL.45 s, 58°C for 2 min, 72°C for 5 min, 1 cycle; 94°C for
30 s, 58°C for 30 s, 72°C for 45 s, with an additional 1-s
extension/cycle, 38 cycles; 94°C for 30 s, 58°C for 30 s,
72°C for 6 min). Primers for detecting full-length RNA
were specific for the pol gene from the SIV parent (outer
primers SIVpolAB, inner primers SIVpolCD) (Joag et al.,
998). Primers specific for multiply spliced mRNAs
panned the introns in tat and rev; a hemi-nested set of
primers was used (Joag et al., 1998; Gunthard et al.,
998). The nested set reactions for MsplBC included 1 M
etaine (Sigma). Temperature cycler profiles for Mspl
rimers were as previously described (Joag et al., 1998).
he lengths of the amplified fragments were: SIVpolAB,
68 nt; SIVpolCD, 646 nt; MsplAB, 131–159 nt; and
splBC, 110–138 nt.
uantitative PCR of plasma viral RNA load
Plasma samples collected in acid citrate dextrose
ACD) or EDTA were analyzed by a real-time RT-PCR
ssay, essentially as previously described (Suryanaray-
na et al., 1998).
athematical modeling of viral dynamics parameters
Viral dynamics parameters, including the basic repro-
uctive ratio (R0), the viral exponential growth rates dur-
ing the intervals of maximal increase for the initial phase
of primary infection (r0), and following withdrawal of treat-
ent (r), and the rate of decline of plasma virus from
eak values following initiation of PMPA treatment (a),
ere calculated as described (Nowak et al., 1997). R0
was estimated according to a standard mathematical
model of viral replication under assumptions of no delay
between initial infection and production of progeny viri-
ons, an exponentially distributed delay, or a fixed delay of
1 day, as described (Nowak et al., 1997). For the un-
treated animals we also determined the initial exponen-
tial growth rate r0, the plasma viral load doubling time t2,
nd the basic reproductive ratio R0.
etermination of pol sequence from treated animals
Viruses isolated from CSF or PBMC cocultures during
CSF) or posttreatment (PBMC) were amplified once in
EMX174 cells. Cell-free supernatant medium from each
ample (1.5 ml) was pelleted at 135,000 g (38,000 rpm) in
Beckman SW50.1 rotor for 15 min at 4°C. The virus
ellets were resuspended in PBS–CMF, and the viral
NA was extracted with the use of the QIAgen viral RNA
it (Qiagen, Chatsworth, CA). One-tenth of the vRNA
ample was amplified by RT-PCR using primers to the
IV polymerase gene (SIVpol A and B) (Joag et al., 1998).
he PCR products were purified using the Wizard PCR
rep (Promega, Madison, WI), and portions of the re-
erse transcriptase sequence were determined from 100
g of the product by direct double-stranded cycle se-
uencing (Bethesda Research Laboratories, Gaithers-urg, MD) using a 32P-labeled primer (SIVpol C) internal
to those used for amplification. Sequence reactions were
separated on modified acrylamide (Long-Ranger; AT Bio-
chemicals, Malvern, PA) gels, as previously described
(Smith et al., 1994) to determine the sequence over the
range of nt 192–393 of the reverse transcriptase.
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